Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-5985

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-5985). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)
A line graph illustrating the percentage of subjects achieving systolic blood pressure (SBP) below 140 mmHg across different baseline SBP values (140-180 mmHg). It compares four treatments: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with distinct markers for each group showing varied efficacy trends.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)
A line graph displaying the percentage of diastolic blood pressure (DBP) below 90 mmHg plotted against baseline DBP values ranging from 90 to 110 mmHg. The graph compares four treatments: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by distinct markers and lines.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)
A line chart depicting the percentage of patients with systolic blood pressure below 130 mmHg relative to baseline systolic blood pressure (mmHg). It compares four groups: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, illustrating the efficacy differences in lowering blood pressure.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)
A line graph depicting the percentage change in diastolic blood pressure (% DBP) from baseline against baseline DBP values (mmHg). The graph includes four data series comparing Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by different markers as indicated in the legend.*
FDA Label Image

Valsartan Structural Formula (Image 05)

Valsartan Structural Formula (Image 05)
Chemical structure diagram of valsartan, one of the active ingredients in the combined pharmaceutical product valsartan and hydrochlorothiazide. The diagram depicts the molecular structure with labeled bonds and rings.*
FDA Label Image

Hydrochlorothiazide Structural Formula (Image 06)

Hydrochlorothiazide Structural Formula (Image 06)
Chemical structure diagram of the active ingredient valsartan, showing its molecular configuration with labeled atoms and bonds. The structure includes a benzene ring with attached functional groups characteristic of valsartan.*
FDA Label Image

Label Image (Lbl500905985)

Label Image (Lbl500905985)
The image shows a white label for Valsartan and Hydrochlorothiazide film-coated tablets, containing 160 mg of valsartan and 25 mg of hydrochlorothiazide per tablet. The label includes storage instructions to keep the product between 68 to 77 degrees Fahrenheit and protect it from moisture and heat. It indicates a quantity of 90 tablets, and the product is labeled by A-S Medication Solutions, Libertyville, Illinois. The label also displays the NDC number 50090-5985-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.